March 17, 2022
Coriolis Pharma and U-Medico Announce a Strategic Alliance
Coriolis Pharma and U-Medico have announced a strategic alliance that includes an equity investment by Coriolis Pharma into U-Medico.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
March 17, 2022
Qbic Announces First Close of New Fund at EUR 49 Million to Invest in Spin-offs from World-class Knowledge Partners
Qbic, an inter-university venture capital fund focusing on the transformation of technological breakthroughs into sustainable businesses, has announced the first close of its third fund at EUR 49 million.
March 16, 2022
Toxys Opens US Office and Production Facility to Accelerate Growth
Toxys BV, a Dutch biotech company that offers a broad spectrum of innovative in vitro toxicology solutions for the safety assessment of novel medicines, (agro)chemicals, cosmetics, and food ingredients, has announced the opening of a sales office in New York (NY) and a production facility in Gaithersburg (DE) to accelerate the company’s growth.
March 16, 2022
V-Bio Ventures’ Portfolio Company Precirix Raises EUR 80m in Series B to Advance its Pipeline of Precision Radiopharmaceuticals
V-Bio Ventures has announced the completion of a EUR 80m Series B round of it’s portfolio company Precirix NV led by new investors INKEF Capital, Jeito Capital and Forbion as co-leads.
March 16, 2022
Lynparza Reduced Risk of Death by 32% in the Adjuvant Treatment of Patients with Germline BRCA-mutated High-risk Early Breast Cancer
Further positive results from the OlympiA Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy.
March 15, 2022
Nosopharm Signs Partnership with INRAE and University of Montpellier to Develop New Anti-infectives
Nosopharm, specialized in exploring unconventional sources of antibiotics to discover new drugs to fight antimicrobial resistance, has signed a collaboration agreement with the DGIMI laboratory.
March 15, 2022
Temedica Announces Cooperation with Bristol Myers Squibb for the Development of a Digital Companion for Psoriasis Patients
Temedica GmbH has announced cooperation with Bristol Myers Squibb to develop a digital companion for patients with psoriasis.
March 15, 2022
Sanofi Announces €300 Million Collaboration with Blackstone Life Sciences to Advance an Innovative Treatment for Multiple Myeloma
Sanofi and Blackstone (NYSE: BX) have announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma (MM).
March 14, 2022
FDA Asks AstraZeneca More Questions About its Chronic Rhinosinusitis Drug
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for AstraZeneca’s Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP).
March 14, 2022
VERAXA Biotech GmbH Appoints Dr. Lars Hufnagel to Chief Technical Officer
Dr. Lars Hufnagel has been appointed Chief Technical Officer (CTO) of VERAXA Biotech, based in Heidelberg, Germany.